The clinical applications of companion diagnostics span diverse oncology indications, from lung and breast cancer to emerging multi-cancer early detection. The Companion Diagnostics Market is benefiting from this diverse demand, valued at USD 9.32 billion in 2025 and projected to reach USD 26.83 billion by 2035 at a CAGR of 11.15%. This article explores the clinical applications driving market growth.

Lung Cancer Applications

Comprehensive Biomarker Testing

Lung cancer drives the largest slice of the companion diagnostics market, reflecting the sheer number of actionable biomarkers now established in NSCLC treatment algorithms. NCCN guidelines mandate testing for at least nine molecular targets before initiating first-line therapy. Lung cancer is the largest indication segment.

EGFR Mutation Testing

EGFR mutation testing is a cornerstone of lung cancer CDx. PCR and NGS platforms are used for EGFR detection. EGFR testing is a high-volume application.

ALK and ROS1 Testing

ALK and ROS1 rearrangement detection is essential for targeted therapy selection. ISH and NGS are used for ALK/ROS1 testing. Fusion testing is a key lung cancer application.

Breast Cancer Applications

HER2 Testing

HER2 testing is a foundational companion diagnostic application. IHC and ISH are used for HER2 detection. HER2 testing is a high-volume breast cancer application.

BRCA1/2 Testing

BRCA1/2 testing identifies patients eligible for PARP inhibitors. BRCA testing is essential for hereditary breast cancer management. BRCA testing is a growing breast cancer application.

PIK3CA Testing

PIK3CA mutation testing identifies patients eligible for targeted therapies. PIK3CA testing is an emerging breast cancer application. Mutation testing is expanding in breast cancer.

Colorectal Cancer Applications

RAS/BRAF Testing

RAS/BRAF testing is essential for anti-EGFR therapy selection in colorectal cancer. RAS/BRAF testing is a high-volume colorectal application. Mutation testing guides targeted therapy decisions.

MSI/MMR Testing

MSI/MMR testing identifies patients eligible for immunotherapy. MSI/MMR testing is a growing colorectal cancer application. Immunotherapy biomarkers are expanding CDx applications.

HER2 Testing in Colorectal Cancer

HER2 testing is emerging in colorectal cancer for targeted therapy selection. HER2 testing is expanding beyond breast cancer. New indications are driving CDx growth.

Melanoma Applications

BRAF Mutation Testing

BRAF mutation testing is essential for targeted therapy selection in melanoma. BRAF testing is a high-volume melanoma application. BRAF is a key melanoma biomarker.

NRAS Mutation Testing

NRAS mutation testing is emerging for targeted therapy selection. NRAS testing is a growing melanoma application. Additional biomarkers are expanding testing.

Immunotherapy Biomarkers

PD-L1 and other immunotherapy biomarkers are used in melanoma. Immunotherapy biomarkers are expanding CDx applications in melanoma. Biomarker testing is essential for immunotherapy selection.

Multi-Cancer Early Detection Applications

MCED Blood Tests

MCED blood tests represent a transformative extension of companion diagnostics into screening populations. The addressable testing volume could exceed 100 million annual screens. MCED platforms create a new revenue category.

Methylation-Based Sequencing

MCED platforms leverage methylation-based sequencing to detect cancer signals across 50+ tumor types. Methylation testing enables pan-cancer detection. MCED technology is a key innovation area.

Screening Population Applications

MCED testing in asymptomatic populations could dramatically expand the addressable market. Screening applications represent a transformative opportunity. Early detection is a key growth driver.

End-User Applications

Pharmaceutical Companies

Pharmaceutical companies remain the largest end-user segment, reflecting their role as funders and co-developers of CDx assays. Pharma drives CDx development and clinical validation.

Reference Laboratories

Hospitals and reference laboratories process the majority of clinical testing volume. Reference labs are a key end-user segment for CDx testing.

CROs

CROs represent the fastest-growing end-user category as pharma sponsors outsource CDx development. CROs handle assay optimization and clinical studies. Outsourcing is driving CRO growth.

Future Clinical Directions

Liquid Biopsy as First-Line Standard

Liquid biopsy will graduate from reflex test to first-line standard in advanced NSCLC and colorectal cancer. First-line liquid biopsy will expand testing access.

Pharmacogenomic Expansion

Pharmacogenomic testing for cardiovascular, psychiatric, and autoimmune drug selection is gaining traction. PGx expansion will open new application layers beyond oncology.

Pan-Cancer Testing Platforms

Platforms integrating genomic, transcriptomic, and proteomic data will emerge. Pan-cancer platforms will expand the addressable market significantly.

The Companion Diagnostics Market continues expanding across clinical applications, from lung cancer to MCED. Companion diagnostics are essential for modern precision medicine, supporting improved outcomes across diverse cancer types and screening populations